2022
1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI
Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Minichiello K, Gandara D, Kelly K, Herbst R. 1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI. Annals Of Oncology 2022, 33: s1033. DOI: 10.1016/j.annonc.2022.07.1173.Peer-Reviewed Original Research
2021
61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLC
Patel S, Reuss J, Scilla K, Giaccone G, Spigel D, Ngiam C, Zhu Q, Bara I, Ding B, Herbst R. 61P IMpower110: Exploratory analyses of the impact of first-line (1L) atezolizumab on the efficacy of next-line of therapy in PD-L1–selected NSCLC. Annals Of Oncology 2021, 32: s1398-s1399. DOI: 10.1016/j.annonc.2021.10.079.Peer-Reviewed Original Research